Strides Arcolab enters alliance with Pfizer

Strides Arcolab enters alliance with PfizerStrides Arcolab, the Bangalore based Pharmaceutical company, has entered into a deal for licensing and supply for medicines with the World's largest drug maker Pfizer.

The deal covers injectables and some oral products from the Indian company along with forty off patent medicines for sale in the US. The financial details of the deal were not disclosed. The first product of the alliance is to be launched as early as 2010.

"Partnering with Pfizer enhances our ability to reach a larger base of customers and patients in need of quality treatment options," said Arun Kumar, CEO Strides Arcolab.

Onco Laboratories Ltd and Onco Therapies Ltd the subsidiaries of Strides and Aspen would supply to the Products Business Unit operated by Pfizer.

President and General Manager of Pfizer's EPBU, Mr. David Simmons said, "We are encouraged about the potential of this relationship."

Experts described it as a good deal for the Bangalore based pharmaceutical company even as it was looking to sell its injectables business. Now the company has decided on an alliance and is set to enter the US market in a big way. On the other hand Pfizer could help expand it to other markets such as Europe, Japan and Korea.

In an earlier deal Strides and its South African partner, Aspen Pharmacare entered into and agreement with GSK in 2008 for emerging markets. Pfizer too entered into similar deals with Aurobindo Pharma and Claris Life Sciences in 2009.